Comparing two treatment lengths for HER2 positive breast cancer before surgery
Part of Cancer clinical trials.
This study compares different lengths of a combination treatment (with drugs that target HER2 plus chemotherapy) given before breast cancer surgery. The goal is to see which treatment plan is safer and more effective for HER2 positive breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old
- You have HER2 positive breast cancer (a specific protein that helps cancer grow)
- Your cancer is only in the breast or nearby lymph nodes, not spread to other organs
- Your heart function measured by an ultrasound is normal or only mildly reduced
- You are generally able to do light activities (ECOG score 0 or 1)
- You have not had major surgery within the last 28 days and are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This study looks at different treatment plans after surgery for people with HER2-positive breast cancer who still have cancer cells remaining after initial chemo and trastuzumab. It aims to see which approach helps improve outcomes.
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.